NanoBRET binding assay for histamine H2 receptor ligands using live recombinant HEK293T cells

Lukas Grätz 1, Katharina Tropmann 1, Merlin Bresinsky 1, Christoph Müller 1, Günther Bernhardt 1 & Steffen Pockes 1,2

Fluorescence/luminescence-based techniques play an increasingly important role in the development of test systems for the characterization of future drug candidates, especially in terms of receptor binding in the field of G protein-coupled receptors (GPCRs). In this article, we present the establishment of a homogeneous live cell-based BRET binding assay for the histamine H2 receptor with different fluorescently labeled squaramide-type compounds synthesized in the course of this study. Py-1-labeled ligand 8 (UR-KAT478) was found to be most suitable in BRET saturation binding experiments with respect to receptor affinity (pKd = 7.35) and signal intensity. Real-time kinetic experiments showed a full association of 8 within approximately 30 min and a slow dissociation of the ligand from the receptor. Investigation of reference compounds in BRET-based competition binding with 8 yielded pKi values in agreement with radioligand binding data. This study shows that the BRET binding assay is a versatile test system for the characterization of putative new ligands at the histamine H2 receptor and represents a valuable fluorescence-based alternative to canonical binding assays.

The histamine H2 receptor (H2R), which is activated endogenously by the biogenic amine histamine (1, Fig. 1), is a long known member of rhodopsin-like receptors (class A), the largest and best studied group of G protein-coupled receptors (GPCRs)1–4. It represents an established target for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer, with H2 antagonists, like cimetidine, ranitidine and famotidine (2–4, Fig. 1) being some of the first blockbuster drugs on the market in the 1970s5. Current research on CNS-penetrating H2R ligands, especially agonists, are ongoing, to get a better understanding of the role of the H2R in the brain, as little is known about that so far6. Since the H2 receptor has been described as being located in postsynaptic neurons and being involved in cognitive processes, it is discussed that stimulation of neuronal H2Rs could have similar positive effects on memory and learning as antagonizing the H3R7–9, which makes the H2R an interesting target for future drug development.

One of the first steps in developing novel ligands is the investigation of binding properties at the respective target. Until now, the characterization of potential ligands in terms of receptor binding is mostly done performing radioligand binding experiments. Despite its high sensitivity, the use of radiolabeled substances is usually connected with some drawbacks. In addition to the constantly increasing costs, the availability as well as the quality of commercial radioligands often declines. Furthermore, the management of radioactive waste is becoming increasingly regulated and expensive. To circumvent these issues, techniques using fluorescently labeled ligands like flow cytometry and the recently described BRET-based binding assay10,11, which has been adapted to several G-protein coupled receptors (GPCRs)12–24, have gained great importance.

For the NanoBRET binding assay the NanoLuc, a genetically engineered luciferase25, is fused to the N-terminus of the GPCR of interest10. After addition of the substrate the enzyme catalyzes an oxidation reaction, which is accompanied by the emission of blue light. Once a suitable fluorescent ligand binds to the tagged receptor, the ligand fluoresces due to bioluminescence resonance energy transfer (BRET). This transfer can only occur when the ligand is in close proximity to the bioluminescent donor, resulting in the observation of a lower nonspecific binding as mainly the receptor-bound fraction of the fluorescent ligand is detected. Additionally, the

1 Institute of Pharmacy, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany. 2 Email: steffen.pockes@ur.de
The ligand binding process can be followed in real time and not only after equilibrium is reached, which gives deeper insight into the kinetic behavior of the ligand.

In this study we established a BRET-binding assay for the histamine H2 receptor. Therefore we synthesized three differently labeled fluorescent ligands (8–10, Fig. 1), structurally derived from BMY-25368 (5, Fig. 1), a potent and long-acting histamine H2 receptor antagonist developed by Brystol-Myers in the 1980s26, and radioligand [3H]UR-DE257 (7, Fig. 1) from our laboratory27,28. These fluorescent tracers were tested for their suitability in the BRET binding assay.

**Results and discussion**

**Synthesis of the fluorescent ligands.** The synthesis of precursor UR-DE36 (6, Fig. 1) was carried out as previously reported in five steps28,29. Subsequently, 6 was treated with the respective labeling reagent (13–15, Fig. 2) in the presence of triethylamine resulting in 8–10. Whereas 14 and 15 were commercially available, 13 was synthesized as described30. Except for 8, aminolyses worked with good yields. Analytical characterization (1H-NMR, HPLC purity) of the fluorescent ligands 8–10 is shown in the Supplementary Figures S1–S6.

**Properties of synthesized ligands.** The chemical stability of the fluorescent H2 ligands 8 (UR-KAT478), 9 (UR-KAT515) and 10 (UR-KAT514) was investigated under assay conditions (pH = 7.4) in binding buffer (BB; composition see Supplementary Information) at room temperature (rt) (Fig. 3, A, B and C1). Compounds 8 and 9 showed no decomposition during 96 h (Fig. 3, A) and 24 h (Fig. 3, B) incubation, respectively, and exhibited excellent chemical stability. The stability test with compound 10 also showed no chemical degradation. However, after only one hour almost no signal corresponding to compound 10 was detectable (Fig. 3, C1), most probably because of adsorption of the ligand to the plastic vessel. This phenomenon could be confirmed visually by staining of the vessel wall and discoloration of the analyte solution. Addition of DMSO to the binding buffer (BB/DMSO 1:1) reduced adsorption, which is depicted in Fig. 3, C2. In order to prevent the adsorption of the

---

**Figure 1.** Structures of reported reference compounds (1–7, 11–12) and the synthesized fluorescent ligands 8–10 for the histamine H2 receptor.
fluorescent ligands in the whole cell-based NanoBRET binding assay, 2% of bovine serum albumin (BSA) were added to the buffer used for all serial dilutions.

For a first pharmacological characterization of the synthesized compounds radioligand competition binding experiments, as well as flow cytometric saturation binding experiments were conducted. All ligands exhibited good affinities in the nanomolar range in both test systems, with 10 showing highest affinities (cf. Table 1; Supplementary Figs. S8, S9). Moreover, we investigated the ligands in a functional test system using a split-luciferase-β-arrestin2 recruitment assay31. All ligands showed antagonistic behavior at the H2R (see Supplementary Figs. S10, S11) and the obtained pKb values supported the findings from the binding assays described above (Table 1).

**Figure 2.** Synthesis of fluorescent ligands 8–10. Reagents and conditions: (i) 6 (1.5 equiv.), NEt3 (7.5 or 11 equiv.), 13, 14 or 15 (1 equiv.), DMF, rt, 2 h.

**Figure 3.** Chromatograms of 8 (A), 9 (B) and 10 (C1 and C2) after different periods of incubation in binding buffer (pH 7.4, A, B, C1) or a mixture of binding buffer (pH 7.4)/DMSO 1:1 (C2) at rt.
BRET-based binding assay at the H2 receptor. Saturation binding experiments. To investigate the suitability of the synthesized fluorescent ligands (8–10) for their use in the BRET-based binding assay, saturation binding experiments were performed at live HEK293T cells stably expressing the NLuc-hH2R. Radioligand competition binding experiments with [3H]UR-DE257 (7) (hH2R, \( K_d = 11.2 \, \text{nM}, c = 20 \, \text{nM} \)) for representative radioligand saturation binding cf. Supplementary Fig. S7) on membrane preparations of Sf9 insect cells expressing the hH2R-Gsα fusion protein as described in the Supplementary Information. Flow cytometric measurements performed at HEK293T-hH2R-q5-HA cells as described in the Supplementary Information. \( \beta \)-arrestin2 recruitment assays performed at HEK293T-ARRB2-H2R cells as described in the Supplementary Information.

Real-time kinetic experiments with 8. For the further characterization of 8, real-time kinetic binding experiments were conducted (Fig. 5). Therefore, 50 nM of 8 were used to measure ligand association to the H2R (Fig. 5, left). The ligand was fully bound to the receptor after approximately 30 min. Dissociation of 8 was initiated by the addition of a 300-fold excess of famotidine (c = 15 µM) after preincubation (60 min) of the cells with fluorescent ligand (c = 50 nM; Fig. 5, right). Slow dissociation kinetics with a dissociation half-life of 300 min were observed and only a small amount of 8 was displaced within 240 min (35–40%). A similar behavior was also reported for the structurally related radioligand 7, leading to the assumption that the pharmacological scaffold is responsible for this type of binding. All kinetic parameters describing the binding of 8 are summarized in Table 2.

Investigation of reported H2R ligands in BRET-based competition binding. To show the versatility of the presented assay principle, we additionally performed BRET-based competition binding experiments with different reported H2 receptor agonists and antagonists, using one fixed concentration of 8 (c = 50 nM) and various concentrations of the respective ligands (Fig. 6). Despite the slow dissociation kinetics of 8, all ligands were able to totally displace the fluorescent tracer after 60 min. It is noteworthy that the displacement curve of histamine

**Table 1.** Pharmacological characterization of the fluorescent ligands 8–10 at the hH2R in binding and functional assays. Data represent mean values ± SEM from N independent experiments, as stated in Table 1, each performed in triplicate. a NanoBRET binding experiments performed at live HEK293T cells stably expressing the NLuc-hH2R. b Radioligand competition binding experiments with [3H]UR-DE257 (7) (hH2R, \( K_d = 11.2 \, \text{nM}, c = 20 \, \text{nM} \)). c Flow cytometric measurements performed at HEK293T-hH2R-q5-HA cells as described in the Supplementary Information. d \( \beta \)-arrestin2 recruitment assays performed at HEK293T-ARRB2-H2R cells as described in the Supplementary Information.
shows a markedly flatter slope (slope ± SEM = −0.55 ± 0.03, N = 5) in comparison to the other tested competitive ligands, which could suggest the existence of a second receptor affinity state, as previously described⁵². However, this could not be clearly confirmed in a competition binding experiment using an extended set of concentrations (cf. Supplementary Fig. S12). Therefore, monophasic binding was assumed for all tested compounds. The pKᵢ values from the BRET competition binding assay are shown in comparison to radioligand binding data are shown in Table 3. Data reported for radioligand binding at CHO hH₂R membranes⁵² are in good accordance with our NanoBRET data obtained at live recombinant HEK293T cells, while data acquired at Sf9 membranes expressing the hH₂R-Gsα₅ fusion protein²⁸ show a larger deviation. It is conspicuous that agonists (1, 11–12) show comparatively higher affinities at Sf9 membranes, whereas antagonists/inverse agonists (2–4) show lower affinities (cf. Table 3). A possible explanation for this observation could be the direct fusion of the receptor with the Gsα₅, since the receptor is thereby permanently brought into an active receptor conformation favoring agonist binding. In contrast, antagonists and especially inverse agonists do not prefer this receptor state, which may lead to the observation of lower binding affinities. This is relevant as cimetidine (2), ranitidine (3) and famotidine (4) are also often described as inverse agonists at the hH₂R, supporting our finding²³–²⁵. Another possibility for the evident discrepancy in the affinity for histamine (1) is the known allosteric effect of sodium on...
performed at CHO membranes\(^3\), we changed the assay procedure by adding sodium in a physiological concentration (c = 145 mM) to the binding buffer. This change resulted in a decrease in affinity for histamine (1) with a \(K_i\) of 4.37 ± 0.02 (N = 3, cf. Table 3) for histamine (1), which is now in good agreement to the binding constant from the BRET binding assay. Taken together the presented BRET-based approach yields comparable binding data for reported histamine H\(_2\) receptor ligands, which confirms the suitability of the test system in combination with the fluorescent ligand 8.

### Conclusion

In this study we report the development of a NanoBRET binding assay for the histamine H\(_2\) receptor including the synthesis and characterization of suitable fluorescent H\(_2\)R ligands. As a homogeneous live cell-based assay, this assay allows for a convenient determination of affinity constants of putative H\(_2\) receptor ligands, independent of their mode of action without any washing or separation steps. The results from our BRET binding assay were well comparable to currently used radioactivity- or fluorescence-based (e.g. flow cytometry) binding assays. Furthermore, real-time kinetic measurements can be performed enabling a better resolved monitoring of ligand-receptor interactions. Prerequisite for the establishment of such assays is the availability of suitable fluorescent ligands. Therefore, we synthesized three differently labeled compounds, all of which have proven to be generally usable in BRET saturation binding experiments. Out of those, substance B turned out to be the best compromise with regard to receptor affinity and signal strength and was successfully used for further investigations. Until now, BRET binding assays have only been described for the histamine H\(_2\) receptors\(^2,3\), making this study close the gap of NanoBRET assays within the histamine receptor family. Thus, selectivity studies, which are essential for the development of new drug candidates, can be carried out using the same assay principle increasing the comparability of results. All in all, this study shows that the BRET binding assay is a valuable test system for the histamine H\(_2\) receptor and provides a novel fluorescence-based alternative to other conventional binding assays.

### Materials and methods

#### Materials.

Dulbecco’s modified Eagle’s medium (DMEM) and HEPES were purchased from Sigma-Aldrich (Munich, Germany). Leibovitz’ L-15 medium (L-15) was from Fisher Scientific (Niddereuth, Germany). Fetal calf serum (FCS), genetin and trypsin/EDTA (0.05%/0.02%) were from Biochrom (Berlin, Germany). Bovine serum albumin (BSA) was sourced from SERVA Electrophoresis (Heidelberg, Germany). Furimazine was from Promega, (Mannheim, Germany). Histamine dihydrochloride was from TCI Chemicals (Tokyo, Japan). Cimetidine was from Sigma-Aldrich (Munich, Germany). Famotidine and ranitidine hydrochloride were from Tocris (Bristol, UK), Acros Organics (Geel, Belgium), Alfa Aesar (Karlsruhe, Germany) and were used as received. The fluorescent dyes BODIPY 630/650 NHS ester and 5-TAMRA NHS ester were purchased from Lumiprobe (Hannover, Germany) or abcr (Karlsruhe, Germany) respectively and used as received. The fluorescent dye Py-1 was synthesized as previously published\(^5\). All solvents were of analytical grade.

#### Synthesis and analytical data.

General. NMR spectra were recorded on a Bruker Avance 600 (1H: 600 MHz) (Bruker, Karlsruhe, Germany) with deuterated solvents from Deuterco (Kastellaun, Germany). HRMS was performed on an Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa...
Clara, CA, USA) using an ESI source. Preparative HPLC was performed with a system from Waters (Milford, Massachusetts, USA) consisting of a 2524 binary gradient module, a 2489 detector, a prep inject injector, fraction collector III and the column was a Phenomenex Kinetic (250 × 21 mm, 5 µm) (Phenomenex, Aschaffenburg, Germany). As mobile phase, mixtures of MeCN and 0.1% aqueous TFA were used. UV detection was carried out at 220 nm. Freeze-drying was carried out using a ScanVac CoolSafe 4-15L freeze dryer from Labogene (LMS, Brigachtal, Germany), equipped with a RZ 6 rotary vane vacuum pump (Vacuubrand, Wertheim, Germany). Analytical HPLC experiments were performed on a 1.100 HPLC system from Agilent Technologies, equipped with Instant Pilot controller, a G1312A Bin Pump, a G1329A ALS autosampler, a G1379A vacuum degasser, a G1316A column compartment and a G1315B DAD detector. The column was a Phenomenex Kinetic XB-C18 column (250 × 4.6 mm, 5 µm) (Phenomenex, Aschaffenburg, Germany), tempered at 30 °C. As the mobile phase, mixtures of MeCN and 0.05% aqueous TFA were used. Gradient mode: MeCN/TFA (0.05%) (v/v) 0 min: 10:90, 30 min: 90:10, 33 min: 95:5, 43 min: 10:90, 50 min: 10:90; flow rate: 0.8 mL/min, t0 = 3.21 min; capacity factor k = (tR − t0)/t0. Absorbance was detected at 220 nm. The purity of the compounds was calculated as the percentage peak area of the analyzed compound by UV detection at 220 nm. The purities of the fluorescent ligands used for pharmaceutical investigation were ≥95%.

**General procedure for the synthesis of the fluorescent ligands.** The amine precursor UR-DE36 (6, (3-(4-Aminobutyl)amino)-4-((3-(3-piperidin-1-ylmethyl)phenoxy)propyl)amino)cyclobut-3-ene-1,2-dione × 2 TFA), was synthesized as previously reported. Following labeling reactions were carried out in 1.5-mL Eppendorf reaction vessels. The amine UR-DE36 (6, 1.5 equiv.) was dissolved in 30 µL of DMF, before NEt3 (7.5 or 11 equiv.) was added. The labeling reagents (1 equiv.) were dissolved in 20 µL of DMF, added to the mixture and the vessel was rinsed twice with DMF (20 µL and 10 µL). The mixture was stirred at room temperature for 2 h. Subsequently, the reaction was stopped by addition of 10% aqueous TFA (20 µL). The crude products were purified by preparative HPLC. The solvent was removed by lyophilization.

(E)-1-((3,4-Diozo-2-((3-(3-piperidin-1-ylmethyl)phenoxy)propyl)amino)cyclobut-1-en-1-yl)amino) (butyl)-2,6-dimethyl-4-(2-(2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-yl)vinyl)pyridin-1-ium (B)†. The title compound was prepared from amine 6 (6.9 mg, 10.8 µmol), Py-1 (1.3 mg, 7.2 µmol) and NEt3 (7.5 µL, 54 µmol) according to the general procedure yielding the product as a red solid (0.98 mg, 15%).

2-(3,6-Bis(dimethylamino)xanthylium-9-yl)-5-((4-((3,4-dioxo-2-((3-(3-(piperidin-1-ylmethyl)phenoxy)propyl)amino)cyclobut-1-en-1-yl)amino)butyl)-2,6-dimethyl-4-(2-(2,3,6,7-tetrahydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-yl)vinyl)pyridin-1-ium (B)†. The title compound was prepared from amine 6 (5.8 mg, 9.0 µmol), 5-TAMRA NHS ester (14, 3.2 mg, 6.0 µmol) and NEt3 (9.3 µL, 67 µmol) according to the general procedure yielding the product as a pink solid (4.02 mg, 70%). RP-HPLC: 96.5% (tR = 13.88 min, k = 4.36). 1H NMR (600 MHz, DMSO-d6) 8.35 (s, 1H), 8.91 (t, J = 5.2 Hz, 1H), 8.28 (d, J = 8.2 Hz, 1H), 8.66 (s, 1H), 7.80–7.74 (m, 2H), 7.38 (t, J = 7.9 Hz, 1H), 7.22–6.66 (m, 8H), 6.85 (d, J = 16.0 Hz, 1H), 6.51 (s, 1H), 3.43–4.28 (m, 2H, 4.22 (d, J = 5.3 Hz, 2H), 4.05 (t, J = 6.0 Hz, 2H), 3.71–3.63 (m, 2H, 3.60–3.51 (m, 2H), 3.25 (t, J = 5.8 Hz, 4H), 2.85 (q, J = 10.9 Hz, 2H), 2.72 (s, 6H), 2.69 (t, J = 6.3 Hz, 4H), 2.03–1.96 (m, 2H), 1.86 (p, J = 6.1 Hz, 4H), 1.83–1.76 (m, 3H), 1.72–1.55 (m, 6H), 1.40–1.29 (m, 1H). HRMS (ESI–MS): m/z [M + H]+ calcld. for C44H56N4O3 + × C4HF6O4: 872.4378; found: 872.4382; C44H56N4O3 × C4HF6O4 (930.00).

(E)-6-(2-(4-(2,5-Difluoro-8-(thiophen-2-yl)-5H-4λ4,5λ4-dipyrrolo[1,3,2-f][1,3,2]diazaborinin-3-yl) vinyl)phenoxy)acetamido)-N-(4-((3,4-diozo-2-((3-(3-piperidin-1-ylmethyl)phenoxy)propyl)amino)cyclobut-1-en-1-yl)amino)butyl)hexamidoxide (A). The title compound was prepared from amine 6 (4.2 mg, 6.5 µmol), BODIPY 630/650 X NHS ester (15.2 mg, 4.3 µmol) and NEt3 (6.6 µL, 47 µmol) according to the general procedure yielding the product as a dark blue solid (3.25 mg, 69%). RP-HPLC: 98.3% (tR = 20.84 min, k = 5.49). 1H NMR (600 MHz, DMSO-d6) 8.19 (s, 1H), 8.12 (t, J = 5.8 Hz, 1H), 8.03 (dd, J = 3.8, 1.1 Hz, 1H), 7.82 (dd, J = 5.0, 1.1 Hz, 1H), 7.78–7.70 (m, 2H), 7.62–7.57 (m, 3H), 7.41–7.34 (m, 3H), 7.30–7.25 (m, 3H), 7.08–7.04 (m, 3H), 7.04–6.99 (m, 2H), 6.94 (d, J = 4.2 Hz, 1H), 4.52 (s, 2H), 4.21 (d, J = 5.2 Hz, 2H), 4.04 (t, J = 6.1 Hz, 2H), 3.66 (s, 3H), 3.31–3.26 (m, 3H), 3.10 (q, J = 6.7 Hz, 2H), 3.02 (q, J = 6.6 Hz, 2H), 2.88–2.79 (m, 2H), 2.52–2.50 (m, 2H), 2.05–1.95 (m, 2H), 1.84–1.76 (m, 2H), 1.70–1.53 (m, 3H), 1.51–1.28 (m, 8H), 1.27–1.14 (m, 2H). HRMS (ESI): m/z [M + H]+ calcld. for C37H46BF2N3O5S: 960.4460; found: 960.4471; C37H46BF2N3O5S × C4HF6O4 (1,073.99).

**Generation of plasmids.** The cDNA coding for the human H1R was purchased from the Missouri cDNA resource centre (Rolla, MO, USA). The plasmid encoding NanoLuc was kindly provided by Promega (Manheim, Germany). The sequences of the receptor and the luciferase were amplified using standard PCR techniques, introducing restriction sites at their respective 5′ and 3′ ends as well as the membrane signal peptide of the murine 5HT3A receptor upstream of the luciferase gene. These were then cloned in-frame into the pcDNA3.1/myc-HIS (B) vector backbone separated by a flexible linker (−SGGGS−) to generate the plasmid encoding the NLuc-H1R. All sequences were verified by sequencing (Eurosinfo Genomics, Ebersberg, Germany).
Cell culture and transfection. All cells were routinely cultivated in DMEM + 10% FCS in a water-saturated atmosphere containing 5% CO₂ at 37 °C and regularly monitored for mycoplasma infection using the Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany). In order to generate stable transfectants, HEK293T wild-type cells were seeded at a density of 3 × 10⁵ cells/mL in a 6-well plate (Sarstedt, Nümbrecht, Germany) one day prior to transfection with 2 μg of cDNA using XtremeGene HP transfection reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s protocol. After two days of incubation (water-saturated atmosphere, 5% CO₂, 37 °C), transfected cells were trypsinized, transferred to a 15 cm cell culture dish (Sarstedt, Nümbrecht, Germany) in DMEM and geneticin was added at a final concentration of 1 mg/mL to select for stable transfectants. After stable growth was observed, concentration of geneticin was reduced to 600 μg/mL.

NanoBRET binding assay. The cell line stably expressing the NLuc-hH1R construct was detached from the cell culture dishes after reaching ~80% confluence by treatment with trypsin/EDTA (0.05%/0.2%, for 2 min at 37 °C) and was centrifuged (600×g, 5 min). The cell pellet was then resuspended in Leibovitz’ L-15 medium (L-15), supplemented with 5% FCS + 10 mM HEPES, and 1.0 × 10⁶ cells/well were seeded in 70 μL (saturation and competition binding) or 80 μL (kinetic experiments) of assay medium into white 96-well cell-Grade™ plates (Brand GmbH & Co. KG, Wertheim, Germany). The cells were then incubated at 37 °C in a humified atmosphere (no additional CO₂) overnight. For saturation binding experiments, serial dilutions (tenfold concentrated) of the fluorescent ligands (8–10) and famotidine (4, 300-fold excess over the respective concentration of fluorescent ligand, non-specific binding) were prepared in dilution buffer (L-15 + 2% BSA + 10 mM HEPES). 10 µL of the fluorescent ligand dilution and 10 µL of L-15 (total binding) or the dilution of 4 (non-specific binding) were added to the cells. After 60 min incubation time at 27 °C, 10 µL of the substrate furimazine, which was diluted according to manufacturer’s protocol beforehand, were added. After 5 min of equilibration time at 27 °C, the measurement was started. Competition binding experiments were performed as described above using one fixed concentration of fluorescent ligand (c = 50 nM) and varying concentrations of the competitors 1–4, 11, 12, that were added at the same time. Kinetic measurements were performed as follows: 10 µL of L-15 (for total binding) or 4 (300-fold excess, c = 15 μM, non-specific binding) were added to the cells. After addition of the diluted substrate, the plate was placed inside the reader for 5 min to equilibrate. To start association 50 µL of a threefold concentrated solution of the fluorescent ligand 8 (c₈final = 50 nM) were added to the adherent cells and the plate was measured for 60 min. Dissociation experiments were conducted in wells, which have been preincubated with 8 as described above for association experiments. To initiate dissociation, 50 µL of a fourfold concentrated solution of 4 (300-fold excess, c₄final = 15 μM) were added to the cells and the measurement was performed for 4 h. All measurements were performed on a TECAN InfiniteLumi plate reader (TECAN, Grödig, Austria) at 27 °C using the Blue2 NB (460 nm ± 35 nm, bandpass) and the Red NB (> 610 nm, longpass) filter combination with an integration time of 100 ms. For the kinetic experiments, integration time was increased to 500 ms for both channels to reduce noise. BRET ratios were calculated by dividing the acceptor emission (red NB) by the donor luminescence (Blue2 NB).

For all BRET binding experiments, specific binding was calculated by subtracting non-specific binding from total binding yielding the “corrected BRET ratio”. For saturation binding experiments, total and non-specific binding were fitted simultaneously using the “one-site total and nonspecific binding” fit. Specific binding was fitted accordingly applying the “one-site specific binding” fit. For competition binding experiments, data were normalized to buffer control (0%) and a 100%-control containing solely fluorescent ligand. The normalized competition binding curves were then fitted with a four-parameter logistic fit yielding pIC₅₀-values. These were normalized to buffer control (0%) and a 100%-control containing solely fluorescent ligand. The normalized fitted accordingly applying the “one-site specific binding” fit. For competition binding experiments, data were normalized to buffer control (0%) and a 100%-control containing solely fluorescent ligand. The normalized competition binding curves were then fitted with a four-parameter logistic fit yielding pIC₅₀-values. These were transformed into pKₐ-values using the Cheng–Prusoff equation.

For kinetic experiments, association experiments were fitted with the “one-phase association” fit yielding Kₐobs, whereas the dissociation experiments were fitted assuming a “one-phase decay” model resulting in Kₐoff. The association rate constant kₐwas was calculated using the following equation: kₐwas = (kₐobs – kₐoff)/c(ligand); c(ligand) = 50 nM. Dissociation half-life t₁/₂ was calculated applying the following formula: t₁/₂ = ln(2)/kₐoff. The kinetic equilibrium dissociation constant Kₐ(diss) was calculated as follows: K(diss) = kₐoff/kₐwas. The errors for kₐwas, t₁/₂, and K(diss) were calculated according to the Gaussian law of error propagation. All experimental data were analyzed using Prism 8 software (GraphPad, San Diego, CA, USA).

Data availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Received: 3 February 2020; Accepted: 24 July 2020

Published online: 06 August 2020

References
1. Lagerström, M. C. & Schiöth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339–357 (2008).
2. Black, J. W., Duncan, W. A. M., Durant, C. J., Ganellin, C. R. & Parsons, E. M. Definition and antagonism of histamine H₂-receptors. Eur. J. Med. Chem. 35, 26–33 (1997).
3. Schwartz, J.-C., Pollard, H. & Quach, T. T. Histamine as a neurotransmitter in mammalian brain: neurochemical evidence. J. Neurochem. 35, 253–278 (1979).
4. Hill, S. J. et al. International Union of Pharmacology. XIII. Classification of histamine H₂-receptors. Pharmacol. Rev. 49, 253–278 (1997).
5. Van Der Goot, H. & Timmerman, H. Selective ligands as tools to study histamine receptors. Eur. J. Med. Chem. 35, 5–20 (2000).
6. Pockes, S., Willing, D., Keller, M., Buschauer, A. & Elz, S. Highly potent, stable, and selective dimeric hetarylpropylguanidine-type histamine H2 receptor agonists. ACS Omega 3, 2865–2882 (2018).

7. Darras, F. H. et al. Synthesis, biological evaluation, and computational studies of tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and H3 receptor antagonists. ACS Chem. Neurosci. 5, 225–242 (2014).

8. Khan, N. et al. The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats. Behav. Brain Res. 297, 155–164 (2016).

9. Sadek, B., Khan, N., Darras, F. H., Pockes, S. & Decker, M. The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats. Physiol. Behav. 165, 383–391 (2016).

10. Stoddart, L. A. et al. Application of BRET to monitor ligand binding to GPCRs. Nat. Methods 12, 661–663 (2015).

11. Stoddart, L. A., White, C. W., Nguyen, K., Hill, S. J. & Pfleger, K. D. G. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding: fluorescence and bioluminescence in ligand binding. Br. J. Pharmacol. 173, 3028–3037 (2016).

12. Stoddart, L. A., Kilpatrick, L. E. & Hill, S. J. NanoBRET approaches to study ligand binding to GPCRs and RTKs. Trends Pharmacol. Sci. 39, 136–147 (2018).

13. Christiansen, E., Hudson, B. D., Hansen, A. H., Milligan, G. & Ulven, T. Development and characterization of a potent free fatty acid receptor 1 (FFAR1) fluorescent tracer. J. Med. Chem. 59, 4849–4858 (2016).

14. Hansen, A. H. et al. Development and characterization of a fluorescent tracer for the free fatty acid receptor 2 (FFAR2/GPR41). J. Med. Chem. 60, 5638–5645 (2017).

15. Sakyiamah, M. M., Nomura, W., Kobayakawa, T. & Tamamura, H. Development of a NanoBRET-based sensitive screening method for CXCRI4 ligands. Bioconjug. Chem. 30, 1442–1450 (2019).

16. Wu, Q.-P. et al. Application of the novel bioluminescent ligand–receptor binding assay to relaxin-RXFP1 system for interaction studies. Amino Acids 48, 1099–1107 (2016).

17. Hoare, B. L. et al. Multi-component mechanism of H2 relaxin binding to RXFP1 through NanoBRET kinetic analysis. Science 11, 93–113 (2019).

18. Wang, J. H. et al. A novel BRET-based binding assay for interaction studies of relaxin family peptide receptor 3 with its ligands. Amino Acids 49, 895–903 (2017).

19. White, C. W., Johnstone, E. K., See, H. B. & Pfleger, K. D. NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing. Cell. Signal. 54, 27–34 (2019).

20. Soave, M., Stoddart, L. A., Brown, A., Woolard, J. & Hill, S. J. Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human β2-adrenoceptor expressed in HEK-293 cells. Pharmacol. Res. Perspect. 4, e00250 (2016).

21. Conroy, S. et al. Synthesis and evaluation of the first fluorescent antagonists of the human P2Y1 receptor based on AR-C118925. J. Med. Chem. 61, 3089–3113 (2018).

22. Stoddart, L. A. et al. Development of novel fluorescent histamine H1 receptor antagonists to study ligand-binding kinetics in living cells. Sci. Rep. 8, 1572 (2018).

23. Mocking, T. A. M., Verweij, E. W. E., Vischer, H. F. & Leurs, R. Homogeneous, real-time NanoBRET binding assays for the histamine H1, and H2 receptors on living cells. Mol. Pharmacol. 94, 1371–1381 (2018).

24. Kozielewicz, P., Bowin, C.-F., Turku, A. & Schulte, G. A NanoBRET-based binding assay for smoothed allows real-time analysis of ligand binding and distinction of two binding sites for BODIPY-cyclopamine. Mol. Pharmacol. 97, 23–34 (2020).

25. Hall, M. P. et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazoypyrizinon substrate. ACS Chem. Biol. 7, 1848–1857 (2012).

26. Cavanagh, R. L. & Buyinsky, J. P. Effect of BMY-25368, a potent and long-acting histamine H2-receptor antagonist, on gastric secretion and aspirin-induced gastric lesions in the dog. Aliment. Pharmacol. Ther. 3, 299–313 (1989).

27. Li, L. et al. Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidiazepam. Bioorg. Med. Chem. Lett. 13, 1717–1720 (2003).

28. Baumeister, P. et al. [3H]UR-DE257: development of a tritium-labeled squaramide-type selective histamine H2 receptor antagonist. ChemMedChem 10, 83–93 (2015).

29. Buschauer, A., Postius, S., Szelényi, I. & Schunack, W. Isohistamine and homologs as components of H2-antagonists. 10, 83–93 (2015).

30. Buschauer, A., Postius, S., Szelényi, I. & Schunack, W. Isohistamine and homologs as components of H2-antagonists. 10, 83–93 (2015).

31. Felixberger, J. Luciferase complementation for the determination of arrestin recruitment: Investigations at histamine and NPY receptors. PhD Thesis, University of Regensburg (2005).

32. Leurs, R., Smit, M. J., Menge, W. M. & Timmerman, H. Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 112, 847–854 (1994).

33. Alewijnse, A. E. et al. Constitutive activity and structural instability of the wild-type human H2 receptor. J. Neurochem. 71, 799–807 (1998).

34. Preuss, H. et al. Mutations of Cys-17 and Ala-271 in the human histamine H2 receptor determine the species selectivity of guanidine-type agonists and increase constitutive activity. J. Pharmacol. Exp. Ther. 321, 975–982 (2007).

35. Preuss, H. et al. Constitutive activity and ligand selectivity of human, guinea pig, rat, and canine histamine H2 receptors. J. Pharmacol. Exp. Ther. 321, 983–995 (2007).

36. Katritch, V. et al. AllostERIC sodium in class A GPCR signaling. Trends Biochem. Sci. 39, 233–244 (2014).

37. Erdmann, D. Histamine H1- and H2-receptor antagonistic synthetic and characterization of radiolabelled and fluorescent pharmacological tools. PhD Thesis, University of Regensburg (2011).

38. Cheng, Y.-C. & Prusoff, W. H. Relationship between the inhibition constant (K) and the concentration of the inhibitor which causes 50% per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108 (1973).
experiments, saturation binding experiments, real-time kinetic experiments and the establishment of the Nano-BRET assay. M.B. performed radioligand binding experiments. C.M. synthesized the Py-1 label 13. L.G. and S.P. initiated and planned the project. S.P. and G.B. supervised the research. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-70332-3.

Correspondence and requests for materials should be addressed to S.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020, corrected publication 2021